|1.||Gershon, David: 1 article (01/2006)|
|2.||Winicov, Irene: 1 article (01/2006)|
|3.||Epstein, Seth P: 1 article (01/2006)|
|4.||Asbell, Penny A: 1 article (01/2006)|
|5.||Srivilasa, Charlie: 1 article (01/2006)|
|6.||Kristic, Katarina J: 1 article (01/2006)|
|7.||Pashinsky, Yevgenia Y: 1 article (01/2006)|
|8.||Schwartz, J A: 1 article (05/2001)|
|9.||Lium, E K: 1 article (05/2001)|
|10.||Silverstein, S J: 1 article (05/2001)|
05/01/2001 - "Collectively, these experiments suggest that CTC-96 is a broad-spectrum inhibitor of infection by enveloped viruses and that it inhibits HSV-1 infection at the point of membrane fusion independent of the type of virus and cellular receptors present."
05/01/2001 - "The experiments described here identify the stage in the virus life cycle where CTC-96 acts and demonstrate that the drug inhibits infection of susceptible cells. "
05/01/1994 - "Following experimental infection of domestic rabbits with CRPV, CTC-96 was applied to infection sites twice daily, 5 days a week for a total of 8 weeks. "
05/01/2001 - "This observation was supported by the failure to detect the accumulation of virus-specified proteins and alpha mRNA transcripts when CTC-96 is present at the onset of infection. "
05/01/1994 - "With increasing dose of CTC-96 we observed tumors earlier, larger, and more often across eight infected sites on each animal."
05/01/1994 - "CTC-96, a cobalt containing complex, was tested as a putative topical therapeutic agent for the treatment of papillomavirus-induced tumors in our cottontail rabbit papillomavirus (CRPV)-rabbit model system. "
|4.||Messenger RNA (mRNA)
|5.||Proteins (Proteins, Gene)